Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability.

The AAPS journal·2026
Same author

George Loizou Obituary.

Toxicology research·2025
Same author

Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for <i>In Vitro</i> Release Testing: Development and Validation.

ACS applied bio materials·2024
Same author

A novel method to derive a human safety limit for PFOA by gene expression profiling and modelling.

Frontiers in toxicology·2024
Same author

Sight impairment registration in Trinidad: trend in causes and population coverage in comparison to the National Eye Survey of Trinidad and Tobago.

Eye (London, England)·2024

Related Experiment Video

Updated: May 30, 2026

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

A Workflow for Global Sensitivity Analysis of PBPK Models.

Kevin McNally1, Richard Cotton, George D Loizou

  • 1Mathematical Sciences Unit, Health and Safety Laboratory Derbyshire, UK.

Frontiers in Pharmacology
|July 21, 2011
PubMed
Summary

Physiologically based pharmacokinetic (PBPK) models aid toxicity testing by integrating data. A new sensitivity analysis (SA) workflow quantifies parameter influences and interactions in PBPK models for better risk assessment.

Keywords:
Lowry plotPBPKalternativesglobal sensitivity analysis

More Related Videos

High-Throughput Metabolic Profiling for Model Refinements of Microalgae
11:07

High-Throughput Metabolic Profiling for Model Refinements of Microalgae

Published on: December 4, 2021

Related Experiment Videos

Last Updated: May 30, 2026

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

High-Throughput Metabolic Profiling for Model Refinements of Microalgae
11:07

High-Throughput Metabolic Profiling for Model Refinements of Microalgae

Published on: December 4, 2021

Area of Science:

  • Pharmacokinetics and Toxicology
  • Computational Biology
  • Risk Assessment

Background:

  • Physiologically based pharmacokinetic (PBPK) models are crucial for predictive toxicity testing.
  • These models integrate diverse in vitro and in vivo data, including alternative toxicity measures and human biomonitoring data.
  • PBPK models incorporate complex non-linear biological processes like enzyme saturation and parameter interactions.

Purpose of the Study:

  • To define a computationally feasible workflow for sensitivity analysis (SA) of PBPK models.
  • To quantify the influence of individual parameters and their interactions within PBPK models.
  • To present SA results intuitively for toxicologists, risk assessors, and regulators.

Main Methods:

  • Developed a workflow for sensitivity analysis (SA) applicable to PBPK models.
  • Ensured the workflow accounts for parameter interactions and non-linear processes.
  • Utilized bar charts and cumulative sum lines (Lowry plots) for data visualization.

Main Results:

  • The proposed SA workflow is computationally feasible.
  • The workflow effectively quantifies parameter influences and interactions.
  • Lowry plots provide an intuitive visualization of SA results.

Conclusions:

  • The developed SA workflow is suitable for PBPK models in toxicity testing.
  • This approach enhances the reliability of PBPK models for risk assessment.
  • The intuitive visualization aids understanding for regulatory and scientific audiences.